| Year |
Citation |
Score |
| 2020 |
Dodd LE, Follmann D, Wang J, Koenig F, Korn LL, Schoergenhofer C, Proschan M, Hunsberger S, Bonnett T, Makowski M, Belhadi D, Wang Y, Cao B, Mentre F, Jaki T. Endpoints for randomized controlled clinical trials for COVID-19 treatments. Clinical Trials (London, England). 1740774520939938. PMID 32674594 DOI: 10.1177/1740774520939938 |
0.352 |
|
| 2019 |
Vernon A, Fielding K, Savic R, Dodd L, Nahid P. The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials. Plos Medicine. 16: e1002884. PMID 31821323 DOI: 10.1371/Journal.Pmed.1002884 |
0.33 |
|
| 2019 |
Dodd LE, Follmann D, Proschan M, Wang J, Malvy D, van Griensven J, Ciglenecki I, Horby PW, Ansumana R, Jiang JF, Davey RT, Lane HC, Gouel-Cheron A. A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. Science Translational Medicine. 11. PMID 31776287 DOI: 10.1126/Scitranslmed.Aaw1049 |
0.33 |
|
| 2019 |
Proschan MA, Dodd LE. Re-randomization tests in clinical trials. Statistics in Medicine. PMID 30672002 DOI: 10.1002/Sim.8093 |
0.325 |
|
| 2018 |
Davey RT, Dodd L, Proschan M, Jahrling P, Hensley L, Higgs E, Lane HC. The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection. The Journal of Infectious Diseases. PMID 30032267 DOI: 10.1093/Infdis/Jiy334 |
0.352 |
|
| 2016 |
Dodd LE, Lantos JD, Pinheiro J. University of Pennsylvania 8th annual conference on statistical issues in clinical trials: Pragmatic clinical trials (morning panel). Clinical Trials (London, England). PMID 27430711 DOI: 10.1177/1740774516657547 |
0.302 |
|
| 2016 |
Dodd LE, Proschan MA, Neuhaus J, Koopmeiners JS, Neaton J, Beigel JD, Barrett K, Lane HC, Davey RT. Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study. The Journal of Infectious Diseases. PMID 26908739 DOI: 10.1093/Infdis/Jiw061 |
0.337 |
|
| 2016 |
Colombo RE, Fiorentino C, Dodd LE, Hunsberger S, Haney C, Barrett K, Nabha L, Davey RT, Olivier KN. A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma. Bmc Infectious Diseases. 16: 54. PMID 26830468 DOI: 10.1186/S12879-016-1358-9 |
0.318 |
|
| 2016 |
Dodd LE. Clinical trials during the Ebola crisis. Clinical Trials (London, England). PMID 26768571 DOI: 10.1177/1740774515621509 |
0.336 |
|
| 2016 |
Proschan MA, Dodd LE, Price D. Statistical considerations for a trial of Ebola virus disease therapeutics. Clinical Trials (London, England). PMID 26768567 DOI: 10.1177/1740774515620145 |
0.318 |
|
| 2015 |
Via LE, England K, Weiner DM, Schimel D, Zimmerman MD, Dayao E, Chen RY, Dodd LE, Richardson M, Robbins KK, Cai Y, Hammoud D, Herscovitch P, Dartois V, Flynn JL, et al. A Sterilizing Tuberculosis Treatment Regimen Is Associated with Faster Clearance of Bacteria in Cavitary Lesions in Marmosets. Antimicrobial Agents and Chemotherapy. 59: 4181-9. PMID 25941223 DOI: 10.1128/Aac.00115-15 |
0.328 |
|
| 2014 |
Coleman MT, Chen RY, Lee M, Lin PL, Dodd LE, Maiello P, Via LE, Kim Y, Marriner G, Dartois V, Scanga C, Janssen C, Wang J, Klein E, Cho SN, et al. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Science Translational Medicine. 6: 265ra167. PMID 25473035 DOI: 10.1126/Scitranslmed.3009500 |
0.311 |
|
| 2014 |
Chen RY, Dodd LE, Lee M, Paripati P, Hammoud DA, Mountz JM, Jeon D, Zia N, Zahiri H, Coleman MT, Carroll MW, Lee JD, Jeong YJ, Herscovitch P, Lahouar S, et al. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Science Translational Medicine. 6: 265ra166. PMID 25473034 DOI: 10.1126/Scitranslmed.3009501 |
0.333 |
|
| 2014 |
Dodd LE, Johnson RF, Blaney JE, Follmann D. Matched longitudinal analysis of biomarkers associated with survival. Clinical and Vaccine Immunology : Cvi. 21: 1145-52. PMID 24943381 DOI: 10.1128/Cvi.00252-14 |
0.309 |
|
| 2014 |
Proschan MA, Dodd LE. A modest proposal for dropping poor arms in clinical trials. Statistics in Medicine. 33: 3241-52. PMID 24757049 DOI: 10.1002/Sim.6169 |
0.334 |
|
| 2013 |
Dodd LE, Korn EL, Freidlin B, Gu W, Abrams JS, Bushnell WD, Canetta R, Doroshow JH, Gray RJ, Sridhara R. An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncology. Clinical Trials (London, England). 10: 754-60. PMID 23935162 DOI: 10.1177/1740774513493973 |
0.326 |
|
| 2013 |
Carroll MW, Jeon D, Mountz JM, Lee JD, Jeong YJ, Zia N, Lee M, Lee J, Via LE, Lee S, Eum SY, Lee SJ, Goldfeder LC, Cai Y, Jin B, ... ... Dodd LE, et al. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy. 57: 3903-9. PMID 23733467 DOI: 10.1128/Aac.00753-13 |
0.334 |
|
| 2013 |
Sridhara R, Mandrekar SJ, Dodd LE. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2613-20. PMID 23669421 DOI: 10.1158/1078-0432.Ccr-12-2938 |
0.352 |
|
| 2013 |
Zhang JJ, Zhang L, Chen H, Murgo AJ, Dodd LE, Pazdur R, Sridhara R. Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2637-45. PMID 23532893 DOI: 10.1158/1078-0432.Ccr-12-3364 |
0.327 |
|
| 2013 |
Dodd LE, Proschan MA. Innovative trial designs to improving tuberculosis drug development. The Journal of Infectious Diseases. 207: 544. PMID 23175767 DOI: 10.1093/Infdis/Jis704 |
0.341 |
|
| 2012 |
Shepherd BE, Shaw PA, Dodd LE. Using audit information to adjust parameter estimates for data errors in clinical trials. Clinical Trials (London, England). 9: 721-9. PMID 22848072 DOI: 10.1177/1740774512450100 |
0.323 |
|
| 2011 |
Dodd LE, Korn EL, Freidlin B, Gray R, Bhattacharya S. An audit strategy for progression-free survival. Biometrics. 67: 1092-9. PMID 21210772 DOI: 10.1111/J.1541-0420.2010.01539.X |
0.355 |
|
| 2010 |
Korn EL, Dodd LE, Freidlin B. Measurement error in the timing of events: effect on survival analyses in randomized clinical trials. Clinical Trials (London, England). 7: 626-33. PMID 20819840 DOI: 10.1177/1740774510382801 |
0.334 |
|
| 2008 |
Albert PS, Dodd LE. On Estimating Diagnostic Accuracy From Studies With Multiple Raters and Partial Gold Standard Evaluation. Journal of the American Statistical Association. 103: 61-73. PMID 19802353 DOI: 10.1198/016214507000000329 |
0.304 |
|
| 2008 |
Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, Mooney MM. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3791-6. PMID 18669467 DOI: 10.1200/Jco.2008.16.1711 |
0.35 |
|
| 2008 |
Dodd LE, Korn EL. Lack of generalizability of sensitivity and specificity with treatment effects. Statistics in Medicine. 27: 1734-44. PMID 17940996 DOI: 10.1002/Sim.3101 |
0.302 |
|
| 2007 |
Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, et al. FDG-PET lymphoma demonstration project invitational workshop. Academic Radiology. 14: 330-9. PMID 17307666 DOI: 10.1016/J.Acra.2006.12.003 |
0.316 |
|
| 2003 |
Dodd LE, Pepe MS. Partial AUC estimation and regression. Biometrics. 59: 614-23. PMID 14601762 DOI: 10.1111/1541-0420.00071 |
0.526 |
|
| 2003 |
Dodd LE, Pepe MS. Semiparametric regression for the area under the receiver operating characteristic curve Journal of the American Statistical Association. 98: 409-417. DOI: 10.1198/016214503000198 |
0.523 |
|
| Show low-probability matches. |